Submit RFP/RFI
Submit RFP/RFI
Search
Submit RFP/RFI
Submit RFP/RFI
Search
Submit RFP/RFI
Submit RFP/RFI
Search

Parkinson’s Disease

Where human focus meets scientific execution.

The Parkinson’s Precision Principle:
Clinical programs built around people, not just protocols

Parkinson’s disease (PD) research is fueled by an extraordinary community, led by those living with the disease and navigating its uncertainty every day. People with Parkinson’s disease choose to enroll in clinical trials knowing progress may be slow, effects uncertain, and benefits not guaranteed. Still, they show up for science again and again, enduring long clinic visits and difficult procedures with the belief that the work truly matters—and with the hope their efforts will lead to better treatments and outcomes for future generations.

At Rho, we execute Parkinson’s clinical trials with that trust and commitment in mind. Our Parkinson’s disease experience connects clinical, operational, regulatory, and data teams around a shared responsibility: conducting studies with respect for the people at the center of them. We partner with sponsors, sites, and study teams to honor that commitment in the day-to-day execution of the trial. Because when patients invest so much in scientific progress, strong execution shouldn’t be optional. It’s what they deserve.

Why Parkinson’s Research Is Different

Parkinson’s disease doesn’t follow a set script, and no two patient journeys are the same. Symptoms evolve unpredictably, response to treatment varies, and progression and outcomes are deeply personal. For participants in Parkinson’s disease clinical trials, this means navigating a demanding disease while also contributing to research that asks even more of them. Their investment is an act of generosity that carries the future of Parkinson’s research forward. That level of dedication raises the standard for how clinical trials should be run. Rho brings deep Parkinson’s disease experience to help keep complex studies grounded, coordinated, and built around people. We always seek to honor the patients behind the data points and the future they are helping to build—not just for themselves, but for everyone.

We’re built to solve the challenges that define Parkinson’s research

Parkinson’s trials require connected teams with deep Parkinson’s disease experience—teams that understand how site realities, patient motivations, and long-term execution affect the study in every way.
Practical support that respects site realities
Access to in-house experts without layers of bureaucracy
Knowledge of the Parkinson’s landscape and patient motivations
Strong partnerships with academic centers and consortia
Scale selection and study design strategy
Building a system that benefits patients, sites, CRAs, and sponsors
Managing complex trials and setting achievable timelines

Spotlight: Parkinson’s Disease Trial Readiness Diagnostic

Is your Parkinson’s trial structured to support patients, caregivers, and investigators? These studies are particularly complex, but they are also significant commitments for everyone involved.

Parkinson’s trials challenge every operational decision you make from day one. Whether it’s your site strategy, timeline management, or long-term continuity plan, teams must execute and perform under real-world conditions. Because behind every Parkinson’s protocol is a highly engaged community placing their trust in the process—and it’s critical to honor their commitment with a study that is stable, interpretable, and achievable over time.

If you need an honest snapshot of your execution readiness, then this diagnostic is for you. Let’s build a Parkinson’s study that’s scientifically sound and delivers meaningful results.

Download

Parkinson’s disease clinical trial capabilities

Our strengths in Parkinson’s disease research reflect what sponsors should expect from a CRO: integrated expertise, practical execution, study designs that respect patients, caregivers, and sites, and a true partnership focused on achieving the sponsor’s goals.
Parkinson’s network insight
Our team brings a deep understanding of the scientific, clinical, and lived-experience dimensions of Parkinson’s disease, helping studies reflect real patient and site needs.
Study design that solves PD challenges
We help sponsors anticipate the complexities of Parkinson’s research—from endpoint selection to operational risks—through disciplined and practical study design.
Proven clinical trial execution
With decades of experience in Parkinson’s and related neurodegenerative conditions, we come prepared to run high-quality studies from day one.
Protocols built around people
Our approach prioritizes patients, caregivers, and sites by shaping endpoints, data flows, and visit schedules to meaningfully reduce burden.

Parkinson’s disease research FAQ

What should sponsors look for in a Parkinson’s CRO for PD trials?
Sponsors should look for a CRO with deep Parkinson’s disease experience, strong site relationships, rater consistency planning, practical study design expertise, the ability to support patients and caregivers over long trial timelines, and alignment with the goals of the sponsor. Rho brings these elements together through integrated teams that understand both the scientific complexity of PD and the human realities behind every study.
Parkinson’s trials are complex because each person’s experience with the disease is unique. Determining how to measure symptoms, maintain rater consistency, and manage site dynamics all influence outcomes. These studies are long and nuanced, requiring sustained commitment from investigators, caregivers, patients, and sponsors. Effective protocols adhere to real PD patient challenges and disease progression. Addressing upstream risks early helps keep the study on track—small inconsistencies can compound over time, making proactive prevention essential.
One of the key challenges in Parkinson’s trials is distinguishing disease modification from symptomatic therapy, and protocols must be designed to support that distinction. Inter-rater variability also creates noise in clinical assessments. Enrollment is often slow, especially in treatment-naïve cohorts, so expectations and timelines need to reflect that reality. Because Parkinson’s is a long and progressive illness, measures must be structured to capture the progression over time. In more lengthy studies, caregiver fatigue can affect adherence, contributing to higher patient dropout rates.
Parkinson’s disease trials are like marathons: patience, precision, and realistic timelines are essential. Treatment-naïve PD populations enroll slowly, much like in rare disease research. High-profile physicians are often the first choice for patients, which can further slow early enrollment. Large, well-known academic centers produce excellent data but typically require longer startup times. A balanced site network—combining major academic centers with smaller, faster-moving sites—delivers the best overall performance.
Successful teams understand the full journey of Parkinson’s patients—from first symptoms to diagnosis, to treatment, and beyond. Participants are often highly motivated, altruistic, and committed to advancing research. For many, taking part in a trial is a way to leave a legacy and contribute to future generations. They are willing to participate in and endure lengthy procedures, and their dedication supports retention. Studies must be designed to honor their time and meet their needs.
Parkinson’s science is unique, and effective research calls for a CRO with deep knowledge of the disease. Patient pathways differ dramatically from other indications—such as pain—and that expertise informs every step of a study, including the design, strategy, patient criteria and selection, vendor oversight, site planning, and operational decisions. The long, progressive nature of Parkinson’s requires measures that capture that progression over time. Wearables, sensors, and scale selection must be used thoughtfully and with a clear purpose.

Rho is advancing Parkinson’s disease research, with experience across 57+ neurology studies at 390+ sites over the last five years—including 11 focused on Parkinson’s disease. These studies are complex and demand strong end-to-end execution. But the people behind the work are what matter most. With more than 30 highly experienced Parkinson’s disease team members at Rho, we collaborate with organizations like the Michael J. Fox Foundation, Parkinson’s Foundation, and David Phinney Foundation to ensure research is both scientifically rigorous and genuinely centered on the Parkinson’s community.

More neuroscience insights from Rho

The Real-World Dynamics Dilemma

Six challenges in acute pain trials and one differentiator—coordinated execution We’ve all been there before. Your acute

Read More
Blog
The Assumption-Reality Paradox

Acute pain trials start with assumptions. How you execute—when reality sets in—determines the outcome. When you’re designing

Read More
Blog
Regulatory Friction You Don’t See Coming in Clinical Development

Early in clinical development, it’s easy to focus on what’s directly in front of you. After all,

Read More
Blog
Parkinson’s Disease Trial Readiness Diagnostic

Parkinson’s disease trials are not only complex studies, but they are long, personal commitments for every patient,

Read More
Guides
The Acute Pain Uncertainty Principle

How confident are you that your acute pain study will behave the way it’s designed to? In

Read More
Guides
When Early Decisions Shape Late-Stage Risk

Early clinical decisions shape regulatory risk and the path to approval   Assumptions about study design and

Read More
Blog

Parkinson’s disease trials are complex. Execute them with confidence.
No matter where you are in your clinical program, Rho brings the experience and judgement to support the people at the heart of every study.

Let’s talk
Scroll to Top